Skeletal Muscle Metastasis from XXXX : 21 cases and review of the literature.

@entity1 @entity5 @entity1358 @entity601 @entity3
OBJECTIVES: This study aimed to raise radiologists' awareness of skeletal muscle metastases (SMM) in @entity1358 ( @entity1358 ) cases and to clarify their imaging appearance. METHODS: A retrospective analysis was undertaken of 21 @entity1 between 44-75 years old with 72 SMM treated from January 1990 to May 2009 at the @entity601 Anderson @entity5 Center in Houston, Texas, USA. Additionally, 37 @entity1 with 44 SMM from a literature review were analysed. RESULTS: Among the 21 @entity1 , the majority of SMM were asymptomatic and detected via computed tomography (CT). Mean @entity3 size was 18.3 mm and the most common site was the trunk muscles (83.3%). The interval between discovery of the primary @entity5 and @entity3 detection ranged up to 234 months. Peripheral enhancement (47.1%) was the most common post-contrast CT pattern and non-contrasted CT lesions were often isodense. Magnetic resonance imaging (MRI) characteristics were varied. Five lesions with available T1-weighted pre-contrast images were hyperintense to the surrounding muscle. Other organ metastases were present in 20 @entity1 . Of the 44 SMM reported in the literature, the majority were symptomatic. Average @entity3 size was 53.4 mm and only 20.5% of SMM were in trunk muscles. The average interval between @entity5 discovery and @entity3 detection was 101 months. Other organ metastases were recorded in 17 out of 29 @entity1 . CONCLUSION: SMM should always be considered in @entity1 with @entity1358 , even well after primary treatment. SMM from @entity1358 may be invisible on CT without intravenous contrast; contrast-enhanced studies are therefore recommended. SMM are often hyperintense to the surrounding muscle on T1-weighted MRI scans.
